Results 151 to 160 of about 2,108 (191)

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report. [PDF]

Am J Case Rep
Sano H, Yanai R, Mitamura Y.
europepmc   +1 more source

Faricimab for Refractory Neovascular Age-Related Macular Degeneration: Retrospective Real-World Evidence from India. [PDF]

Clin Ophthalmol
Biswas RK, Sheth JU, Shrivastava V, Kaur J, Sinha S, Pal SS, Nandi K, Das S.   +7 more
europepmc   +1 more source

MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.

Ophthalmologica
Zhou AW, Sahraravand RA, Baumann LM, Teagle GM, Brown J, Pieramici D, Holy SE, Borne MJ, Wong RW, Cunningham MA, Pearce WA, Rahman EZ, Chang M, Bhavsar AR, Brown DM, Alfaro DV, Fan KC, Cehofski LJ, Ip M, Sadda SR, Lesmes LA, Ehlers JP, Chaudhary V, Al-Khersan H, Wykoff CC.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Faricimab

Reactions Weekly
  +18 more sources

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials [PDF]

Lancet, The, 2022
Arshad M Khanani, Frank G Holz, Timothy Y Y Lai   +2 more
exaly   +3 more sources

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials [PDF]

Lancet, The, 2022
Francis Abreu, Zdenka Haskova, Anat Loewenstein   +2 more
exaly   +3 more sources

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies [PDF]

Drug Design, Development and Therapy, 2023
Degenerative eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are major contributors to significant vision loss in developed nations.
Georgios D Panos, Matteo Ripa
exaly   +3 more sources

Global experience of faricimab in clinical settings - a review

Expert Opinion on Biological Therapy
Faricimab is a bispecific antibody that acts to reduce neoangiogenesis in exudative retinal vascular disorders. It is approved for use in neovascular age-related macular degeneration and diabetic macular edema. We review the published efficacy and safety of faricimab in clinical settings.A comprehensive literature review was conducted.
Ashish Sharma, Nilesh Kumar, Francesco M Bandello   +2 more
exaly   +4 more sources

Efficacy of treatment with faricimab for patients with refractory nAMD

European Journal of Ophthalmology
Objective To investigate the efficacy of treatment with faricimab in patients with refractory neovascular age-related macular degeneration (nAMD). Methods A Single-centre, retrospective cohort study was conducted on patients treated with faricimab for refractory nAMD.
Sajjad Mahmood
exaly   +3 more sources